Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer

Gene Therapy

Volumn 7, Issue 4, 2000, Pages 321-328

  Li, Y ^a   Starr, S E ^a   Lisziewicz, J ^b,c   Ho, W Z ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Research Institute for Genetic and Human Therapy   (United States)

^c NONE   (Italy)

Author keywords

Antitat; Gene therapy; HIV 1; Latency

Indexed keywords

CD4 ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE; RNA; RNA DIRECTED DNA POLYMERASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; MONONUCLEAR CELL; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TIME; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENES, TAT; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; VIRUS ACTIVATION; VIRUS REPLICATION;

ALPHAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0033993546     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301088     Document Type: Article

References (29)

1. Hammer SM et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New Engl J Med 1997; 337: 725-733.
2. Gulick RM et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl J Med 1997; 337: 734-739.
3. Ho D. HIV-1 survives drug onslaught by hiding out T cells. Science 1997; 278: 122-123.
4. Wong JK et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
5. Finzi D et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
6. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999; 5: 512-517.
7. Chun TW et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-188.
8. Chun TW et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Med 1995; 1: 1284-1290.
9. Gilboa E, Smith C. Gene therapy for infectious diseases: The AIDS model. Trends Genet 1994; 10: 139-144.
10. Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Therapy 1994; 1: 13-26.
11. Morgan RA. Gene therapy for HIV infection. Clin Exp Immunol 1997; 107: 41-44.
12. Bridges SH, Sarver N. Gene therapy and immune restoration for HIV disease. Lancet 1995; 345: 427-432.
13. Lisziewicz J et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993; 90: 8000-8004.
14. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC. Antitat gene therapy: A candidate for late-stage AIDS patients. Gene Therapy 1995; 2: 218-222.
15. Lisziewicz J et al. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J Virol 1995; 69: 206-212.
16. Buonaguro L et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66: 7159-7167.
17. Lafrenie RM et al. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997; 159: 4077-4083.
18. + hematopoietic progenitor cells with an antitat gene protects T cell and macrophage progeny from AIDS virus infection. J Virol 1997; 71: 2740-2746.
19. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993; 57: 183-289.
20. Folks TM et al. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-802.
21. Folks TM et al. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristlate acetate. J Immunol 1988; 140: 1117-1122.
22. Folks TM et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T cell clone. Proc Natl Acad Sci USA 1989; 86: 2365-2368.
23. Chen BK, Saksela K, Andino R, Baltimore D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 1994; 68: 654-660.
24. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retrovir 1992; 8: 191-197.
25. Rosenberg ZF, Fauci AS. Immunopathogenesis of HIV infection. FASEB J 1991; 5: 2382-2390.
26. Ho WZ et al. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments. AIDS Res Hum Retrovir 1998; 14: 1573-1580.
27. Saksela K et al. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol 1993; 67: 7423-7427.
28. + T cells using a combination of cytokines (published erratum appears in J Exp Med 1998; 188: Following 614). J Exp Med 1998; 188: 83-91.
29. Willey RL et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988; 62: 139-147.